This network meta-analysis compares weight loss and adverse events with available drug treatments for obesity, including liraglutide, naltrexone-bupropion, and lorcaserin.
Because 36% of US adults are obese with many unable to lose weight to improve health, Yanovski and Yanovski systematically review medications currently approved for obesity treatment and discuss off-label use of medications studied for obesity and use of obesity medications in clinical practice.
This Medical Letter review summarizes information about liraglutide, a GLP-1 receptor agonist approved for long-term weight weight management in adults with a body mass index (BMI) of 30 or greater, or in those with a BMI of 27 or greater plus weight-related comorbidity such as hypertension, dyslipidemia, or diabetes.
This Viewpoint discusses the potential use of combined naltrexone extended-release plus bupropion extended-release for adjunctive treatment of obesity.
Kushner and Ryan review current best practices for assessment and lifestyle management of obesity and describe how updated guidelines can be applied to individual patients.